Evidence map›Paper›PMID 41383505›Full record

ArticleFrontiers in oncology2025

Case Report: A case of intrahepatic papillary neoplasm of the bile duct with invasive carcinoma in a young patient and review of the literature.

Linhui Hu, Hua Wan, Yuan Hong, Li Liang, Yan Wang

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Linhui Hu *Department of Infectious Disease, Peking University First Hospital, Beijing, China.
Hua Wan *Department of Infectious Disease, Peking University First Hospital, Beijing, China.
Yuan HongDepartment of Infectious Disease, Peking University First Hospital, Beijing, China.
Li LiangDepartment of Pathology, Peking University First Hospital, Beijing, China.
Yan WangDepartment of Infectious Disease, Peking University First Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Intrahepatic papillary neoplasm of the bile duct (IPNB) with invasive carcinoma is a rare cholangiocarcinoma with the most frequent site of origin being intrahepatic bile ducts. Given its rarity and non-specific clinical presentations, accurate diagnosis plagues clinicians to improve patient outcomes. Case presentation: We present a case of a 31-year-old male who initially exhibited fever. Routine ultrasonography and computed tomography (CT) revealed a large mass in the right liver lobe, suggesting a high likelihood of an infectious lesion. However, multidisciplinary discussion offered a variety of possible scenarios. The patient subsequently underwent an extended right hepatectomy (ERH), and histopathological examination suggested a intrahepatic IPNB with invasive adenocarcinoma. Clinical discussion: The diagnosis and management of IPNB remain challenging, particularly in patients who present with atypical clinical symptoms and lack significant abnormalities in laboratory tests. Early imaging plays a critical role in guiding the diagnostic process. However, comprehensive diagnostic speculations, clinical expertise, and even invasive detections are essential for establishing a definitive diagnosis and determining the appropriate treatment strategy. Given the potential to invasive carcinoma, early detection and resection are vital to improving prognosis.

Indexed as

carcinomadiagnosisfeverintrahepatic papillary neoplasm of the bile ductprognosis

Identifiers

PMID41383505
PMCPMC12690561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.